BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 2816596)

  • 1. [Cell kinetic study of urogenital tumors utilizing in vitro BrdU-labelling method and anti-BrdU monoclonal antibody].
    Shimabukuro T; Yamamoto M; Mitsui H; Yamamoto N; Sakatoku J; Harada H; Sacho T
    Hinyokika Kiyo; 1989 Aug; 35(8):1285-90. PubMed ID: 2816596
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Non-urothelial tumors of the urinary tract].
    Mikuz G
    Verh Dtsch Ges Pathol; 1993; 77():180-98. PubMed ID: 7511278
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pathologic features of bladder tumors after nephroureterectomy or segmental ureterectomy for upper urinary tract transitional cell carcinoma.
    Raman JD; Sosa RE; Vaughan ED; Scherr DS
    Urology; 2007 Feb; 69(2):251-4. PubMed ID: 17320658
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic impact of p63 and p53 expression in upper urinary tract transitional cell carcinoma.
    Zigeuner R; Tsybrovskyy O; Ratschek M; Rehak P; Lipsky K; Langner C
    Urology; 2004 Jun; 63(6):1079-83. PubMed ID: 15183954
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of p27 and its ubiquitin ligase subunit Skp2 in upper urinary tract transitional cell carcinoma.
    Langner C; von Wasielewski R; Ratschek M; Rehak P; Zigeuner R
    Urology; 2004 Sep; 64(3):611-6. PubMed ID: 15351619
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Association of uPA and uPAR expression with invasive behaviors of urinary transitional cell carcinoma].
    Li YJ; Zheng BZ; Zhou ZL
    Ai Zheng; 2004 Jun; 23(6):704-6. PubMed ID: 15191676
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Urothelial carcinoma of the upper urinary tract: comparison between the WHO/ISUP 1998 consensus classification and WHO 1999 classification system.
    Holmäng S; Johansson SL
    Urology; 2005 Aug; 66(2):274-8. PubMed ID: 16098355
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Clinical studies on renal pelvic and ureteral carcinoma].
    Akino H; Ishida H; Ito Y; Tanase K; Isomatsu Y; Muranaka K; Mori H; Kanamaru H; Okada K
    Hinyokika Kiyo; 1997 Apr; 43(4):257-62. PubMed ID: 9161851
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Cell kinetic study of human carcinomas using bromodeoxyuridine and immunohistochemistry].
    Kikuyama S
    Nihon Geka Gakkai Zasshi; 1989 Mar; 90(3):355-63. PubMed ID: 2770679
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transitional cell carcinoma of the upper urinary tract: analysis of morphology and distribution for surgical management.
    Fujimoto H; Tobisu K; Mizutani T; Sakamoto M; Kakizoe T
    Jpn J Clin Oncol; 1993 Oct; 23(5):303-8. PubMed ID: 8230755
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact factors on prognosis of patients with pT3 upper urinary tract transitional cell carcinoma.
    Wu CF; Pang ST; Chen CS; Chuang CK; Chen Y; Lin PY
    J Urol; 2007 Aug; 178(2):446-50, dicussion 450. PubMed ID: 17561129
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The prognostic value of KI-67 proliferation index in transitional cell carcinoma of renal pelvis and ureter].
    Korneev IA
    Vopr Onkol; 2005; 51(2):211-5. PubMed ID: 16223003
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Minichromosome maintenance protein 2 expression in normal kidney and renal cell carcinomas: relationship to tumor dormancy and potential clinical utility.
    Rodins K; Cheale M; Coleman N; Fox SB
    Clin Cancer Res; 2002 Apr; 8(4):1075-81. PubMed ID: 11948116
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinical study on renal pelvic and ureteral tumors].
    Okumura A; Yokoyama T; Muraishi Y; Nagakawa O; Sakamoto M; Kazama T; Fuse H; Katayama T
    Hinyokika Kiyo; 1994 Sep; 40(9):777-80. PubMed ID: 7801838
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Flow cytometric bromodeoxyuridine (BrdU)/DNA analysis--study with urogenital tumors].
    Shimabukuro T; Yoshihiro S; Matsuyama H; Yamamoto N; Sakatoku J
    Hinyokika Kiyo; 1989 Oct; 35(10):1653-7. PubMed ID: 2610171
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 5-Bromodeoxyuridine incorporation and PCNA expression as measures of cell proliferation in transitional cell carcinoma of the urinary bladder.
    Waldman FM; Carroll PR; Cohen MB; Kerschmann R; Chew K; Mayall BH
    Mod Pathol; 1993 Jan; 6(1):20-4. PubMed ID: 8093979
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The protective role of renal parenchyma as a barrier to local tumor spread of upper tract transitional cell carcinoma and its impact on patient survival.
    Park J; Ha SH; Min GE; Song C; Hong B; Hong JH; Kim CS; Ahn H
    J Urol; 2009 Sep; 182(3):894-9. PubMed ID: 19616243
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlation between iododeoxyuridine and MIB-1 labelling index in gastric carcinoma and adjacent normal gastric tissue.
    Schipper DL; Wagenmans MJ; Peters WH; Wobbes T; Wagener DJ
    Anticancer Res; 2000; 20(2A):707-14. PubMed ID: 10810344
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Urothelial cancer of the upper urinary tract].
    Jurincic-Winkler C; Horlbeck R; Gasser A; Glenewinkel J; Klippel KF
    Urologe A; 1993 Jul; 32(4):295-9. PubMed ID: 8372411
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Surveillance of urothelial carcinoma: stage and grade migration, 1993-2005 and survival trends, 1993-2000.
    David KA; Mallin K; Milowsky MI; Ritchey J; Carroll PR; Nanus DM
    Cancer; 2009 Apr; 115(7):1435-47. PubMed ID: 19215030
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.